Mode
Text Size
Log in / Sign up
Phase 1 N=47 Randomized Triple-blind Treatment

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis/Bladder Pain Syndrome

Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Change From Baseline for Worst Bladder Pain/Discomfort Scores Overnight / Over-the-day — -0.7; -1.6; -0.8; -1.7 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
V117957 (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Imbrium Therapeutics
Primary completion
Jan 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline for Worst Bladder Pain/Discomfort Scores Overnight / Over-the-day
-0.7; -1.6; -0.8; -1.7

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.

Eligibility Criteria

Key Inclusion Criteria include:

  • Female, age ≥18 years and capable of voiding independently. Able to comply with acceptable methods of contraception.
  • Diagnosis of IC/BPS or meets criteria for IC/BPS as defined by the American Urology Association as "an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms for more than six weeks duration, in the absence of infection or other identifiable causes".
  • Subject has Bladder Pain/Interstitial Cystitis Symptom Scale (BPIC-SS) total score of ≥19 and worst bladder pain/discomfort sub-score of ≥4 to ≤9.
  • Has undergone evaluation to rule out other conditions that cause bladder pain/discomfort. Any microscopic or gross hematuria that has not been evaluated in the past 12 months will require appropriate clinical evaluation to determine study eligibility.

Key Exclusion Criteria include:

  • Pelvic floor tenderness in the absence of bladder tenderness on physical examination by primary investigator.
  • Urinary tract infection (UTI) within the past 30 days, or history of recurrent UTI.
  • Hematuria determined to be associated with bladder malignancy or other significant pathology.
  • Had surgical procedure at any time that affected bladder function.
  • Received intravesical therapy or had bladder hydrodistension, fulguration, botulinum toxin, or triamcinolone bladder injection, percutaneous nerve stimulation. A subject receiving such treatment(s) prior to screening is eligible if in the opinion of the investigator the procedure/ treatment resulted in no notable or enduring effect and subject continues to exhibit stable symptomology.
  • Has current or history of clinically significant kidney disease or abnormal kidney function, or nephrolithiasis.

Other protocol-specific inclusion and exclusion criteria may apply.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06285214). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search